Gapping up
In reaction to strong earnings/guidance:
- CRC +28.3%, LOCO +11.9%, NPTN +11.7%, ITT +11.1%, QRVO +10.2%, ERII +9.6%, FTNT +8.5%, BRKR +5.6%, X +5.6%, NWL +5.4%, CPT +5%, AYX +4.9%, RMAX +4.6%, BAH +4.6%, BGG +4.6%, ACLS +4.2%, CWST +4%, FTAI +3.9%, SSNC +3.8%, PFSI +3.8%, BLDR +3.3%, HTH +3%, SEM +2.9%, JCOM +2.8%, HAE +2.7%, IBP +2.7%, PMT +2%, OEC +1.9%, SNR +1.7%, MELI +1.6%, CCJ +1.5%, OPI +1.2%, EGO +1.1% (also reports positive Kisladag mine test results, and progress in Greece), NVO +1%, XOM +1%
Other news:
- BGNE +26.5% (BeiGene announces global strategic oncology collaboration with Amgen; Amgen to purchase approximately $2.7 bln of BeiGene shares)
- SWKS +3.5% (following QRVO results)
Analyst comments:
- AXNX +5.9% (initiated with an Overweight at Piper Jaffray)
- NTLA +5.4% (upgraded to Outperform from Mkt Perform at Raymond James)
- SRPT +3.5% (initiated with a Buy at Guggenheim)
- UPWK +3.3% (initiated with a Outperform at First Analysis Sec)
- TAL +2.4% (upgraded to Buy from Neutral at Goldman)
- RYN +0.7% (upgraded to Buy from Neutral at DA Davidson)